Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

ConclusionsIn the tofacitinib RA clinical development program, lymphoma rates were stable over time and there were minimal differences in baseline characteristics of patients with and without lymphoma.This article is protected by copyright. All rights reserved.

Source: Arthritis Care and Research - September 21, 2017 Category: Rheumatology Authors: Xavier Mariette, Connie Chen, Pinaki Biswas, Kenneth Kwok, Mary G. Boy Tags: Original Article Source Type: research